Pfizer and BioNTech can file an EUA revision to use its COVID-19 vaccine on young Filipinos in the Philippines, according to VEP Head.
Vaccine Expert Panel (VEP) head Dr. Nina Gloriani on Wednesday said that Pfizer and BioNTech can file an application to revise its existing emergency use authorization (EUA) so that its jointly-developed COVID-19 vaccine can also be used on young Filipinos.
Recently, the United States Food and Drug Administration (US FDA) expanded the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine to include children aged 12 to 15 years old.
According to Gloriani, the vaccine manufacturer can take the same track in the Philippines.
“Hintayin na lang po natin na mag-apply sila ng EUA sa atin, actually this is an amendment to the EUA that we already have. We actually look forward to that kasi maaaddress nya ang pagbabakuna sa isang age group na hindi makakaya with the other vaccines,” Gloriani said in a media briefing.
Pending expansion, Pfizer was allowed for use in the Philippines for people aged 16 years and older. All other COVID-19 vaccines currently available in the Philippines were for those aged 18 years old and above.
Gloriani also said that aside from Pfizer, Janssen Pharmaceuticals and Moderna were also doing a study on COVID-19 vaccine efficacy among the younger population.